Bcl-2 inhibitor APG-2575 for use in chronic lymphocytic leukemia or small lymphocytic lymphoma in Phase Ib/II clinical, approved by NMPA

Ascentage Pharma announced that it has received approval from the State Drug Administration of China (NMPA) for its Ib/II phase of its new Bcl-2 selective inhibitor APG-2575 to treat recurrent/refractive chronic lymphoma or small lymphocytic lymphoma (r/r CLL/SLL)this open-labelEd Ib/II dose increase and dose extension study is designed to assess the safety, tolerance and initial anticancer activity of Patients with APG-2575 as a single drug or combination therapy for r/r CLL/SLLAPG-2575 is a new oral Bcl-2 selective inhibitor developed by AXA Pharmaceuticals to restore normal apoptosis in cancer cells by selectively blocking Bcl-2, thus treating a variety of blood system malignanciesrecent studies have shown that Bcl-2 inhibitors can be effective in treating CLL/SLL, and that Bcl-2 inhibitors in combination with Bruton tyrosine kinase inhibitors or CD20 monoclonal antibodies can improve patient response and extend patient survivalPrevious Phase I studies of APG-2575 monotherapy in the United States, Australia and China have shown good safety and anti-cancer activity, and preliminary data support ongoing clinical studies of APG-2575CLL/SLL is a hematological malignant tumor caused by mature B-cell tumor, which mainly affects the elderly populationThe disease is characterized by the accumulation of cancerous lymphocytes in peripheral blood, bone marrow, spleen and lymph nodesThe incidence of CLL/SLL has been increasing with the aging of the Chinese and changes in diet and lifestyle